Growth through acquisitions Everest has a track record of strategic acquisitions (Brightech International in 2022 and August Research in 2023) to expand capabilities and geographic reach, signaling opportunities to position cross-sell of advanced data analytics, biostatistics, and full-service CRO offerings to acquired client bases and new regions.

Global footprint With headquarters in Canada and offices in the US, China, Taiwan, and Bulgaria, Everest offers multinational trial capabilities and potential for expansion into additional markets, presenting sales angles for globally centralized trials, region-specific regulatory support, and harmonized data management.

Biostatistics leadership Origin as a statistical and data management center of excellence suggests strong capabilities in biostatistics, programming, and data analytics that can be leveraged to upsell advanced statistics, data visualization dashboards, and integrated analytics services to sponsors seeking robust data-driven decision making.

Quality and service Brand positioning around quality, customer focus, and flexibility creates opportunities to target sponsors seeking reliable, client-centric CRO partners for complex programs, late-stage trials, or programs requiring adaptable resourcing and rapid on-boarding.

Financial and growth signals Revenue in the mid-range hundred millions and recent M&A activity indicate a growing scale with potential for expanded service lines, cross-selling to the existing client base, and pursuing larger phase programs or device/drug combination studies aligned with Everest’s capabilities.